EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

05.12.18

The EPO’s ‘Inventor Award’ Scam: Part II

Posted in Deception, Europe, Patents at 12:08 am by Dr. Roy Schestowitz

Andane Remmal

Summary: The sorts of people whom Battistelli’s EPO grants awards to are sometimes literal frauds and sometimes people who, according to domain experts, did not even deserve the patent they got a prize for

THE EPO is a highly abusive organisation. We’d go further and say corrupt, albeit that typically leads the EPO to trying to SLAPP us. We have never ever seen anything remotely like it at the USPTO, which is reasonably professional. We focus on patent scope there (this has improved in recent years). The USPTO maintains neutrality on patents; no rankings or “awards” (a form of special endorsement)…

EPO insiders can’t stop talking about next month’s event, which will be the passage of EPO budget to Saint-Germain-en-Laye.

As one comment put it a couple of days ago: “Hadn’t you noticed that the EPO is currently under the – I am almost tempted to add “totalitarian” – political control of the deputy mayor of Saint-Germain-en-Laye?”

Does nobody in the mainstream media see the problem with that? It’s not only against the rules (for public servants in international institutions); putting aside the passage of EPO money to Saint-Germain-en-Laye…

“Does nobody in the mainstream media see the problem with that? It’s not only against the rules (for public servants in international institutions); putting aside the passage of EPO money to Saint-Germain-en-Laye…”The remark is in the fifth comment by the way, responding to “MaxDrei” (mentioned/quoted here in relation to its context).

But this post is not about the scandal of Battistelli’s ‘alleged’ misuse of budget or even the award to a literal fraud (whom the EPO now tries to distance itself from — very, very belatedly). This post relates to our first part, which spoke about Morocco, a former French colony which Battistelli seems to be oftentimes leveraging for political agenda. This post is about award for EP1879655B1 (“Advanced [sic] Scientific [sic] Developments” [sic] led by Mr. Remmal).

How much of an invention was it really? Someone who is familiar with this scientific domain looked more closely at it. I should disclose that it’s well outside my field of specialty, so I mostly rely on others for this assessment, which was carried out anonymously.

“How much of an invention was it really?”“It is about the mentioned patent granted to Remmal,” told us a source, “who got the EPO inventor award last year.

“In my opinion there was a lot ado about nothing in the Gazette.”

There was an article about it the Gazette, in French even! [Page 1, Page 2]

“In the present case I am not questioning the probity of Mr. Remmal,” our source said, “but he is definitely NOT the genius that the EPO makes out of him.

“Clinical phytotherapy is a research field since the early 70s. Synergistic effects were investigated with antibiotics alone, and are the basis of aromatherapy. Yet the combination of essential oils and antibiotics and corresponding synergistic effects have been disclosed in 2003 already. See this publication: Bacterial resistance modifying agents from Lycopus europaeus.”

From the Abstract: “As part of an ongoing project to identify plant natural products which modulate bacterial multidrug resistance (MDR), bioassay-guided isolation of an extract of Lycopus europaeus yielded two new isopimarane diterpenes, namely methyl-1alpha-acetoxy-7alpha 14alpha-dihydroxy-8,15-isopimaradien-18-oate (1) and methyl-1alpha,14alpha-diacetoxy-7alpha-hydroxy-8,15-isopimaradien-18-oate (2). The structures were established by spectroscopic methods. These compounds and several known diterpenes were tested for in vitro antibacterial and resistance modifying activity against strains of Staphylococcus aureus possessing the Tet(K), Msr(A), and Nor(A) multidrug resistance efflux mechanisms. At 512 microg/ml none of the compounds displayed any antibacterial activity but individually in combination with tetracycline and erythromycin, a two-fold potentiation of the activities of these antibiotics was observed against two strains of S. aureus that were highly resistant to these agents due to the presence of the multidrug efflux mechanisms Tet(K) (tetracycline resistance) and Msr(A) (macrolide resistance).

Our source continued to stress “that predates the priority date. (2005). Note that this document wasn’t cited – unfortunately – in the search report. This document does not quote carvacrol, carveol or alpha-ionone as constituents of essential oils. But carvacrol and carveol were already known at that time for their antibiotic effect . I see no inventive step there. In my opinion the inventor of the year 2017 was awarded a prize on the basis of an unduly granted patent.”

Research into this has gone on for at least a week. It’s not a rushed judgment. As our source put it, having consulted others as well, “the more I look into the Remmal case, the more I believe we have explosive material. I had the document I referred to double-checked by a specialist and yes I can say that the granted claims do not have the required inventive step.

“But there is more than that. The company owned by Mr.Remmal, Advanced Scientific Developments, is an asset management firm (gestion de valeur mobilere).”

On the day of the priority date (13/5/2005) Mr. Remmal filed 4 applications, namely:

  • US20080171709A1: Pharmaceutical composition comprising an antiviral agent, an antitumoral agent or an anti-parasitic agent, and active agent selected among carveol, thymol, eugenol, borneol and carvacrol.
  • US20080214568A1: pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol, carvacrol, and alpha- and beta-ionones.
  • US20080171768A1: pharmaceutical composition containing an anti-parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone.
  • US20080214518A1: pharmaceutical composition comprising an antibacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol.

“The last one in its EPO version is the patent on which Remmal received the “inventor” award,” our source remarked. “On all 4 patents the addition of essential oils exhibits a notable synergistic effect, not only with antibiotics but also with antifungal, anti-parasitic, anti-tumoral, antiviral agents. If all this was true, Mr. Remmal would deserve a Nobel prize, not just a dubious EPO inventor award prize.”

“I have also checked the publications by Remmal,” the source noted. “The number and scope of the publications is an indicator of a scientist’s activity. Here is a list. What I see are many publications in the field of essential oils and their medical uses. All these papers are published by Remmal at al but none deals with the use of essential oils in combination with other medications. I find very awkward that none of the publications addresses the subject for which the EP patent was applied for.

“To close the subject, an article published just after Mr. Remmal was awarded the EPO inventor prize [is] a very touching article that looks more like self promotion. I don’t want to judge someone without having an in-depth knowledge of the situation, but considering all the facts I have made my opinion and it is not positive. Frankly, I believe that Remmal is just another troll. What do you think?”

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

What Else is New


  1. Language Patent Lawyers Are Using to Warp the Debate and Decrease Public Understanding of Patents

    The patent microcosm, trying to get the public all baffled/confused about the patent system, continues (mis)using words to convey things in misleading ways



  2. USPTO FEES ACT Makes the US Patent Office a Money-Making Machine That Systematically Disregards Patent Quality

    The lingering issues with patent assessment at the US patent office, which unlike US courts isn't quite so impartial an actor (it benefits more from granting than from rejecting)



  3. Guest Post on Ronan Le Gleut and Benalla at the French Senate (in Light of Battistelli's Epic Abuses)

    Thoughts on the possibility that Battistelli will belatedly be held accountable for his abuses, knowing that a senator representing French Citizens residing Abroad comes from the EPO



  4. A Lot of US Patents Are Entirely Bogus, But Apple Was Willing to Pay for Them

    Apple's resistance to Qualcomm's patent aggression was preceded by very heavy ("thermonuclear" by Steve Jobs' description/words) patent wars against Android and even legitimisation of clearly bogus software patents from Amazon



  5. 'Owning' Nature, Thanks to Patent Insanity and People Who Profit From That

    Questionable patents on things that always existed and are merely being explained or reassembled; those sorts of patents typically serve to merely discredit the patent system and courts too increasingly reject such patents (e.g. SCOTUS on Mayo Collaborative Services and Myriad Genetics, Inc.)



  6. Patents Stranger Than Fiction and 'Protection' From Fictional Things

    Fictional things are being treated like "inventions" and insurance companies now look to exploit fear of fictional things (man-made concepts), such as ownership of mere ideas or words



  7. Benoît Battistelli Refuses to Talk to the Media About Bringing Firearms to the EPO

    Benoît Battistelli's highly aggressive approach has attracted the attention of French media; Battistelli has reportedly refused to comment on that matter, knowing that he lacks a defense (same thing happened after he had hauled millions of EPO euros to his other employer)



  8. Patent Law Firms Have Become More Like Marketing Departments With an Aptitude for Buzzwords

    What we're observing, without much reluctance anymore, is that a lot of patent lawyers still push abstract software patents, desperately looking for new trendy terms or adjectives by which to make these seem non-abstract



  9. Interlude: The Need to Counter Misinformation From the Patent and Litigation 'Industry'

    24,500 posts reached; so we pause and reflect, seeing that many sites/blogs of patent maximalists gradually ebb away



  10. Advocacy of the Unitary Patent System Has Become Almost Identical to the 'Leave' (Brexit) Campaign

    The charades of Team UPC carry on in Kluwer Patent Blog — a blog which for a very long time served no purpose other than Unified Patent Court (UPC) advocacy



  11. Open Invention Network is Rendered Obsolete in the Wake of Alice and It's Not Even Useful in Combating Microsoft's Patent Trolls

    Changes at the US Patent and Trademark Office (USPTO) and in US courts' outcomes may have already meant that patent trolls rather than software patents in general are a growing threat, including those that Microsoft is backing, funding and arming to put legal pressure on GNU/Linux (and compel people/companies to host GNU/Linux instances on Azure for patent 'protection' from these trolls)



  12. Bogus Patents Which Oughtn't Have Been Granted Make Products Deliberately Worse, Reducing Innovation and Worsening Customers' Experience

    How shallow patents — or patent applications that no patent office should be accepting — turn out to be at the core of multi-billion-dollar cases/lawsuits, with potentially a billion people impacted (their products made worse to work around such questionable patents)



  13. EPO is Like a Patent Litigation (Without Actual Trial) Office, Not a Patent Examination Office

    Examination of patent applications isn't taken seriously by an office whose entire existence was supposed to be about examination; bureaucracy at the top of this office has apparently decided that the sole goal is to create more demand (i.e. lawsuits) for the litigation 'industry'



  14. Philippe Cadre From the French National Institute of Industrial Property (INPI) Wants to Join António Campinos

    Yet another example of INPI's creeping influence if not 'entryism' at the EPO and this time too patent quality isn't a priority



  15. Links 22/9/2018: Mesa 18.2.1, CLIP OS, GPL Settlement in Artifex/First National Title Insurance Company

    Links for the day



  16. Links 21/9/2018: Cockpit 178, Purism 'Dongle'

    Links for the day



  17. Criticism of Unitary Patent (UPC) Agreement Doomed the UPC and Patent Trolls' Plan -- Along With the Litigation Lobby -- for Unified 'Extortion Vector'

    The Unitary Patent or Unified Patent Court (UPC) was the trolls' weapon against potentially millions of European businesses; but those businesses have woken up to the fact that it was against their interests and European member states such as Spain and Poland now oppose it while Germany halts ratification



  18. It Wasn't Judges With Weapons in Their Office, It Was Benoît Battistelli Who Brought Firearms to the European Patent Office (EPO)

    The EPO scandals deepen in light of a very major scandal which has occupied the French media for a couple of months



  19. Links 20/9/2018: 2018 Linux Audio Miniconference and Blackboard's Openwashing

    Links for the day



  20. Links 19/9/2018: Chromebooks Get More DEBs, LLVM 7.0.0 Released

    Links for the day



  21. Links 18/9/2018: Qt 5.12 Alpha , MAAS 2.5.0 Beta, PostgreSQL CoC

    Links for the day



  22. Today's European Patent Office (EPO) Works for Large, Foreign Pharmaceutical Companies in Pursuit of Patents on Nature, Life, and Essential/Basic Drugs

    The never-ending insanity which is patents on DNA/genome/genetics and all sorts of basic things that are put together like a recipe in a restaurant; patents are no longer covering actual machinery that accomplishes unique tasks in complicated ways, typically assembled from scratch by humans; some supposed 'inventions' are merely born into existence by the natural splitting of organisms or conception (e.g. pregnancy)



  23. The EPO Has Quit Pretending That It Cares About Patent Quality, All It Cares About is Quantity of Lawsuits

    A new interview with Roberta Romano-Götsch, as well as the EPO's promotion of software patents alongside CIPA (Team UPC), is an indication that the EPO has ceased caring about quality and hardly even pretends to care anymore



  24. Qualcomm's Escalating Patent Wars Have Already Caused Massive Buybacks (Loss of Reserves) and Loss of Massive Clients

    Qualcomm's multi-continental patent battles are an effort to 'shock and awe' everyone into its protection racket; but the unintended effect seems to be a move further and further away from 'Qualcomm territories'



  25. Links 17/9/2018: Torvalds Takes a Break, SQLite 3.25.0 Released

    Links for the day



  26. The Patent Trial and Appeal Board (PTAB) Helps Prevent Frivolous Software Patent Lawsuits

    PTAB with its quality-improving inter partes reviews (IPRs) is enraging patent maximalists; but by looking to work around it or weaken it they will simply reduce the confidence associated with US patents



  27. Abstract Patents (Things One Can Do With Pen and Paper, Sometimes an Abacus) Are a Waste of Money as Courts Disregard Them

    A quick roundup of patents and lawsuits at the heart of which there's little or no substance; 35 U.S.C. § 101 renders these moot



  28. “Blockchain” Hype and “FinTech”-Like Buzzwords Usher in Software Patents Everywhere, Even Where Such Patents Are Obviously Bunk

    Not only the U.S. Patent and Trademark Office (USPTO) embraces the "blockchain" hype; business methods and algorithms are being granted patent 'protection' (exclusivity) which would likely be disputed by the courts (if that ever reaches the courts)



  29. Qualcomm's Patent Aggression Threatens Rationality of Patent Scope in Europe and Elsewhere

    Qualcomm's dependence on patent taxes (so-called 'royalties' associated with physical devices which it doesn't even make) highlights the dangers now known; the patent thicket has grown too "thick"



  30. Months After Oil States the Patent Maximalists Are Still Desperate to Crush PTAB in the Courts, Not Just in Congress and the Office

    Patent Trial and Appeal Board (PTAB) inter partes reviews (IPRs) improve patent quality and are therefore a threat to those who profit from spurious feuding and litigation; they try anything they can to turn things around


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts